Patent ID: 8067417

Claim:
A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein Ring A is an imidazole ring wherein the ring is optionally substituted with C 1-6 haloalkyl, halo, NO 2 , —OH, —CN or C 1-6 alkyl; X 1 is —NR 8 — R 1 is H, C 1-10 aliphatic, C 3-10 cycloaliphatic, C 6-10 aryl, 5-10 membered heteroaryl, or 3-10 membered heterocyclyl, wherein said R 1 is optionally substituted with 0-5 J 1 ; Each R 2 and R 3 is independently H, or C 1-3 alkyl; R 4 is H, C 1-10 aliphatic, or C 3-10 cycloaliphatic, wherein said R 4 is optionally substituted with 0-5 J 4 ; R 8 is H, C 1-6 aliphatic, C 3-8 cycloaliphatic, —C(O)R, —C(O)OR, or —C(O)NRR′; Each J 1 is independently C 1-6 haloalkyl, halo, NO 2 , CN, Q, or -Z-Q, or two J 1 taken together can optionally form ═O; Each Z is independently C 1-6 aliphatic in which 0-3—CH 2 — units in said C 1-6 aliphatic are optionally replaced with —NR—, —O—, —S—, —C(O)—, —C(═NR)—, —C(═NOR)—, —S(O)—, or —S(O) 2 —, wherein any non-replaced —CH 2 — units in said C 1-6 aliphatic are optionally substituted with 0-2 J Z ; Each Q is independently H, C 1-6 aliphatic, a 3-8-membered aromatic or non-aromatic monocyclic ring having 0-3 heteroatoms independently selected from O, N, and S, or an 8-12 membered aromatic or non-aromatic bicyclic ring system having 0-5 heteroatoms independently selected from O, N, and S, wherein each Q is independently optionally substituted with 0-5 J Q ; Each J Z is independently halo, C 1-6 aliphatic, C 3-6 cycloaliphatic, NO 2 , CN, OH, NH 2 , NH(C 1-4 aliphatic), N(C 1-4 aliphatic) 2 , —O(C 1-4 aliphatic), —CO 2 H, —CO 2 (C 1-4 aliphatic), —O(haloC 1-4 aliphatic), or halo(C 1-4 aliphatic); Each J Q , and J 4 is independently -M or -Y-M; Each Y is independently an unsubstituted C 1-6 aliphatic in which 0-3 —CH 2 — units in said C 1-6 aliphatic are optionally replaced with —NR—, —O—, —S—, —C(O)—, —S(O)—, or —S(O) 2 —; Each M is independently H, C 1-6 aliphatic, C 3-6 cycloaliphatic, halo(C 1-4 aliphatic), O(haloC 1-4 aliphatic), 3-6 membered heterocyclyl, halo, NO 2 , CN, OH, OR′, SH, SR′, NH 2 , NHR′, N(R′) 2 , COH, COR′, CO 2 H, CO 2 R′, CONH 2 , CONHR′, CON(R′) 2 , OCOR′, OCONH 2 , OCONHR′, OCON(R′) 2 , NHCOR′, NR′COR′, NHCO 2 R′, NR′CO 2 R′, NHCO 2 H, NR′CO 2 H, NHCONH 2 , NHCONHR′, NHCON(R′) 2 , SO 2 NH 2 , SO 2 NHR′, SO 2 N(R′) 2 , NHSO 2 R′, or NR′SO 2 R′; Each R is independently H or unsubstituted C 1-6 aliphatic; and Each R′ is unsubstituted C 1-6 aliphatic, or two R′ groups, together with the atom to which they are bound, form an unsubstituted 3-8 membered saturated or partially unsaturated monocyclic ring having 0-1 heteroatoms independently selected from O, N, and S.